search
Back to results

Genes and Other Risk Factors for Second Primary Breast Cancer in Women With Breast Cancer and Their Female Family Members and Friends

Primary Purpose

Breast Cancer

Status
Unknown status
Phase
Locations
United Kingdom
Study Type
Observational
Intervention
DNA analysis
genetic linkage analysis
loss of heterozygosity analysis
polymorphism analysis
laboratory biomarker analysis
medical chart review
questionnaire administration
Sponsored by
Cancer Research UK
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Breast Cancer focused on measuring breast cancer

Eligibility Criteria

undefined - 70 Years (Child, Adult, Older Adult)FemaleAccepts Healthy Volunteers

DISEASE CHARACTERISTICS:

  • Meets 1 of the following criteria:

    • Women who have been diagnosed with contralateral or unilateral breast cancer
    • Family controls, including sisters and adult daughters of contralateral cases, female relatives by marriage
    • Unrelated controls (i.e., friends)
  • Hormone receptor status not specified

PATIENT CHARACTERISTICS:

  • Pre- or postmenopausal

PRIOR CONCURRENT THERAPY:

  • Not specified

Sites / Locations

  • London School of Hygiene and Tropical MedicineRecruiting

Outcomes

Primary Outcome Measures

Prevalence of polymorphisms in candidate genes in contralateral patients and controls
Prevalence of alleles in breast cancer patients from multiple-case families and those in blood-unrelated family controls
Linkage analysis to detect new susceptibility genes in larger multiple-case families combined with data on families previously collected by the Institute of Cancer Research
Relationships between candidate gene polymorphisms and hormone levels in relatives and controls

Secondary Outcome Measures

Average hormone levels in contralateral patients' first-degree relatives and controls

Full Information

First Posted
May 9, 2009
Last Updated
August 23, 2013
Sponsor
Cancer Research UK
search

1. Study Identification

Unique Protocol Identification Number
NCT00896818
Brief Title
Genes and Other Risk Factors for Second Primary Breast Cancer in Women With Breast Cancer and Their Female Family Members and Friends
Official Title
The British Breast Cancer Study - National Cancer Research Network Cohort (BBC-NCRN)
Study Type
Observational

2. Study Status

Record Verification Date
June 2009
Overall Recruitment Status
Unknown status
Study Start Date
January 2005 (undefined)
Primary Completion Date
January 2009 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Cancer Research UK

4. Oversight

5. Study Description

Brief Summary
RATIONALE: Studying samples of blood, urine, and tumor tissue in the laboratory from patients with cancer and their female relatives and friends may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at genes and other risk factors for second primary breast cancer in women with breast cancer and in their female family members and friends.
Detailed Description
OBJECTIVES: To identify new breast cancer susceptibility alleles in breast cancer patients and family controls. To compare the prevalence of known polymorphisms in genes involved in hormonal activation and degradation pathways in breast cancer patients and family controls. To correlate these polymorphisms with quantitative intermediate markers of susceptibility to breast cancer, such as circulating hormone levels and mammographic density. To perform linkage analysis to detect new susceptibility genes in larger multiple-case families combined with data on families previously collected by the Institute of Cancer Research. To evaluate the relationship between these polymorphisms and hormone levels in relatives and family controls. To compare average hormone levels in patients' unaffected first-degree relatives with family controls using urine samples from premenopausal women and urine and/or serum samples from postmenopausal women. To perform follow-up in a cohort of unaffected first-degree relatives at moderate-to-high risk of developing breast cancer with prospective questionnaire data and hormone measurements. OUTLINE: Unaffected and affected first-degree female relatives and family or friend controls undergo blood sample collection once during study. Genomic DNA is purified from the blood samples for genetic analyses. Within a cohort of unaffected first-degree relatives, postmenopausal women also provide a single urine sample for hormonal assays. Hormones analyzed in the serum and/or urine of postmenopausal women include estradiol, estrone, sulphate, prolactin, androstenedione, testosterone, progesterone, 17-hydroxyprogesterone, and SHBG. Unaffected premenopausal women within the cohort provide urine samples on 6 successive days around the midpoint of their menstrual cycle and on one day towards the luteal phase of their menstrual cycle. These samples are analyzed for luteinizing hormone and metabolites of estradiol and progesterone (i.e., creatinine ratios for estrone glucuronide and pregnanediol glucuronide). Access to case notes, mammograms, and archival tumor blocks and accompanying pathology reports of breast cancer patients and their affected relatives is requested. When tumor samples from both tumors in bilateral cases are available, these samples are analyzed to identify regions of loss of heterozygosity in which both tumors have lost the same chromosomal region. Cancer patients and controls, including affected or unaffected first-degree relatives, relatives by marriage, or friends complete a questionnaire at baseline to provide information on demographics (i.e., personal and family), cancer diagnosis and treatment (if applicable), and known risk factors for breast cancer (i.e., lifestyle, reproductive behavior, and family history). Study participants may be followed periodically for cancer incidence and cause-specific mortality. Peer Reviewed and Funded or Endorsed by Cancer Research UK.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
breast cancer

7. Study Design

8. Arms, Groups, and Interventions

Intervention Type
Genetic
Intervention Name(s)
DNA analysis
Intervention Type
Genetic
Intervention Name(s)
genetic linkage analysis
Intervention Type
Genetic
Intervention Name(s)
loss of heterozygosity analysis
Intervention Type
Genetic
Intervention Name(s)
polymorphism analysis
Intervention Type
Other
Intervention Name(s)
laboratory biomarker analysis
Intervention Type
Other
Intervention Name(s)
medical chart review
Intervention Type
Other
Intervention Name(s)
questionnaire administration
Primary Outcome Measure Information:
Title
Prevalence of polymorphisms in candidate genes in contralateral patients and controls
Title
Prevalence of alleles in breast cancer patients from multiple-case families and those in blood-unrelated family controls
Title
Linkage analysis to detect new susceptibility genes in larger multiple-case families combined with data on families previously collected by the Institute of Cancer Research
Title
Relationships between candidate gene polymorphisms and hormone levels in relatives and controls
Secondary Outcome Measure Information:
Title
Average hormone levels in contralateral patients' first-degree relatives and controls

10. Eligibility

Sex
Female
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
DISEASE CHARACTERISTICS: Meets 1 of the following criteria: Women who have been diagnosed with contralateral or unilateral breast cancer Family controls, including sisters and adult daughters of contralateral cases, female relatives by marriage Unrelated controls (i.e., friends) Hormone receptor status not specified PATIENT CHARACTERISTICS: Pre- or postmenopausal PRIOR CONCURRENT THERAPY: Not specified
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julian Peto, MD
Organizational Affiliation
London School of Hygiene and Tropical Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
London School of Hygiene and Tropical Medicine
City
London
State/Province
England
ZIP/Postal Code
WC1E 7HT
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julian Peto, MD
Phone
44-20-7927-2632
Email
julian.peto@lshtm.ac.uk

12. IPD Sharing Statement

Learn more about this trial

Genes and Other Risk Factors for Second Primary Breast Cancer in Women With Breast Cancer and Their Female Family Members and Friends

We'll reach out to this number within 24 hrs